Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

ClinicalTrials.gov ID: NCT06810505

Public ClinicalTrials.gov record NCT06810505. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world. Participants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks. Participants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing questionnaires.

Study identification

NCT ID
NCT06810505
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
420 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 12, 2025
Primary completion
Feb 28, 2031
Completion
Feb 28, 2031
Last update posted
Sep 2, 2026

2025 – 2031

United States locations

U.S. sites
31
U.S. states
16
U.S. cities
31
Facility City State ZIP Site status
Rehabilitation and Neurological Services /ID# 270782 Huntsville Alabama 35805 Recruiting
Preferred Research Partners - Fayetteville /ID# 270419 Fayetteville Arkansas 72703 Completed
Preferred Research Partners /ID# 270389 Little Rock Arkansas 72211 Recruiting
Advanced Research Center /ID# 270257 Anaheim California 92805 Recruiting
Neuro Pain Research Center /ID# 271048 Fresno California 93710 Recruiting
Accellacare - Long Beach /ID# 270398 Long Beach California 90807 Recruiting
Excell Research /ID# 270258 Oceanside California 92056 Recruiting
Lumos Clinical Research Center /ID# 270582 San Jose California 95124 Recruiting
Sunwise Clinical Research /ID# 270431 Walnut Creek California 94596 Recruiting
Northwest Florida Clinical Research Group, LLC /ID# 270833 Gulf Breeze Florida 32561 Recruiting
Auzmer Research /ID# 271158 Lakeland Florida 33813 Completed
My Preferred Research /ID# 270312 Miami Florida 33155 Recruiting
Encore Medical Research - Weston /ID# 271139 Weston Florida 33331 Recruiting
Pediatric Neurology & Epilepsy Center Of Central Florida - Winter Park /ID# 275263 Winter Park Florida 32789 Recruiting
Deaconess Midtown Hospital /ID# 270572 Evansville Indiana 47710 Recruiting
Michigan Headache & Neurological Institute /ID# 270942 Ann Arbor Michigan 48104 Recruiting
Proven Endpoints LLC /ID# 270269 Ridgeland Mississippi 39157 Recruiting
Cct Research - Papillion Research Center /ID# 270393 Papillion Nebraska 68046 Recruiting
Healthy Perspectives - Innovate Mental Health Services /ID# 270847 Nashua New Hampshire 03060 Recruiting
Dent Neurologic Institute - Amherst /ID# 270260 Amherst New York 14226 Recruiting
Headache Wellness Center /ID# 270568 Greensboro North Carolina 27405 Completed
Frontier Clinical Research - Scottdale /ID# 270854 Scottdale Pennsylvania 15683 Recruiting
Frontier Clinical Research - Smithfield /ID# 270849 Smithfield Pennsylvania 15478 Recruiting
Access Clinical Trials Inc /ID# 270280 Nashville Tennessee 37203 Recruiting
UT Health Austin at Dell Childrens Neurology Clinic /ID# 270577 Austin Texas 78723-3079 Recruiting
Earle Research /ID# 270424 Houston Texas 77058 Recruiting
Clinpoint Trials /ID# 270261 Waxahachie Texas 75165 Recruiting
Pantheon Clinical Research /ID# 270259 Bountiful Utah 84010 Recruiting
Alpine Research Organization - Clinton /ID# 276527 Clinton Utah 84015 Recruiting
Highland Clinical Research /ID# 270281 Salt Lake City Utah 84124 Recruiting
Frontier Clinical Research - Kingwood /ID# 271053 Kingwood West Virginia 26537 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06810505, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 2, 2026 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06810505 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →